688166 Stock Overview
A pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
BrightGene Bio-Medical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥31.39 |
| 52 Week High | CN¥41.39 |
| 52 Week Low | CN¥19.63 |
| Beta | 0.33 |
| 1 Month Change | -2.36% |
| 3 Month Change | 29.28% |
| 1 Year Change | -3.95% |
| 3 Year Change | -12.61% |
| 5 Year Change | -1.69% |
| Change since IPO | 2.55% |
Recent News & Updates
Recent updates
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 28% Price Boost Is Out Of Tune With Earnings
Oct 01
Is BrightGene Bio-Medical Technology (SHSE:688166) Using Too Much Debt?
Sep 19Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding
Aug 01BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up
May 21BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 01Shareholder Returns
| 688166 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.5% | -1.9% | -1.2% |
| 1Y | -3.9% | -1.8% | 11.8% |
Return vs Industry: 688166 matched the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 688166 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 688166 volatility | |
|---|---|
| 688166 Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688166's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688166's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,208 | Jiandong Yuan | www.bright-gene.com |
BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection. It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, cerebrovascular, iron supplement, digestion, and other APIs and intermediates.
BrightGene Bio-Medical Technology Co., Ltd. Fundamentals Summary
| 688166 fundamental statistics | |
|---|---|
| Market cap | CN¥13.25b |
| Earnings (TTM) | CN¥188.08m |
| Revenue (TTM) | CN¥1.24b |
70.4x
P/E Ratio10.7x
P/S RatioIs 688166 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688166 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.24b |
| Cost of Revenue | CN¥571.33m |
| Gross Profit | CN¥670.14m |
| Other Expenses | CN¥482.05m |
| Earnings | CN¥188.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 53.98% |
| Net Profit Margin | 15.15% |
| Debt/Equity Ratio | 91.3% |
How did 688166 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield21%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 05:35 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BrightGene Bio-Medical Technology Co., Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue Gao | Changjiang Securities Co. LTD. |
| Shitong Han | Citic Securities Co., Ltd. |
| Yu Wu | CMB International Securities Limited |